Chinese Academy of
Sciences Protein
Science core facility
Center |
|
|
IBP Seminar: Development of Peptide Therapeutics |
| Author: |
|
Update time: |
2010-03-24 |
|
| what: |
Development of Peptide Therapeutics |
| who: |
Dr. Gary Woodnutt
Vice President, CovX of Pfizer |
| when: |
Friday, March 26, 2010
15：00 p.m. |
| where: |
Lecture Hall in Library, Institute of Biophysics |
| Host: |
Ruiming Xu, Professor |
| More Information: |
Abstract
Peptides have promise as potent and selective drug candidates but have not succeeded primarily because of poor pharmacokinetics. The fusion of these peptides to our scaffold antibody has produced molecules that have the advantage of the peptide activity but with pharmacokinetics determined by the scaffold. Examples will be discussed that have enabled rapid SAR to be carried out producing pre-clinical and clinical candidates with optimized activity and pharmacokinetics.
Dr. Gary Woodnutt
Gary Woodnutt received his doctoral degree in Biochemistry and Physiology from Leeds University in 1982. He worked extensively in small molecule Discovery and Development for Infectious Disease and Supportive Care indications while at GlaxoSmithKline, eventually attaining the role of Vice President of Biology in the Anti-Infective Center of Excellence. He moved to oversee Biotherapeutic and Natural Product discovery at Diversa in 2001 expanding the early stage technology into therapies for Oncology and Metabolic Disease. He joint CovX in 2006 to oversee the Biology efforts in early stage discovery and development of therapies for Oncology and Metabolic Disease and was pivotal in the discussions with Pfizer leading to purchase of CovX in 2008. Since the purchase he has been extensively involved in expanding the potential for CovX technology use in other therapeutic areas ( Pain, COPD, anti-infective, Inflammation and Immunology) including the development of bifunctional technology to further expand therapeutic uses and the initiation of Phage Discovery Efforts. Currently Vice president of Biology he continues to expand collaborative links internally with the newly acquired Wyeth organization as well as with Academic and Biotechnology Companies.
|
|
|
|
|
